

Cold urticaria triggered after amoxicillin-clavulanic acid treatment

García-Paz V^{1,2}, Romero-Sánchez L³, Otero-Alonso A⁴, González-Rivas M⁴, Fernández-Franco I⁴, Vila Sexto L²

¹Allergy Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

²Pediatric Allergy Unit, Department of Pediatrics, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

³Allergy Department, Complejo Hospitalario Universitario de Vigo, Vigo (Pontevedra), Spain

⁴Allergy Department., Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela (A Coruña), Spain

All authors have contributed equally

Corresponding author:

Vanesa García Paz

Department of Allergy, Complejo Hospitalario Universitario de A Coruña (CHUAC)

Street As Xubias, s/n

15009, A Coruña, Spain.

E-mail: vanesa.garcia.paz@sergas.es

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0907

Key words: Cold urticaria. Amoxicillin. Urticaria.

Palabras clave: Urticaria por frío. Amoxicilina. Urticaria.

Cold urticaria (ColdU), a chronic inducible urticaria subtype (CIndU) is characterized by appearance of wheals and/or angioedema with risk of anaphylaxis and life-threatening reactions, in response to cold exposure (air, solids or liquids) of the skin or mucosa [1–5]. Its prevalence in patients with chronic urticaria and CIndU is 7.62% and 26.1% respectively [2]. Diagnosis is based on clinical history (mainly in atypical forms) as well as cold provocation tests (ice cube and/or Temp Test) [1,4–6]. Treatment is based on cold avoidance, second-generation H1-antihistamines in increasing dose until reaching clinical control [7], and Omalizumab used off-label [4,5].

We report the case of a 32-year-old female patient without atopy who developed ColdU after treatment with amoxicillin-clavulanic acid. Due to a tract urinary infection in 2016, she was prescribed Amoxicillin-clavulanate for ten days. Seven days after ending treatment she presented outbreaks of wheals. Initially she did not associate it with any trigger, but later she noticed outbreaks of urticaria after being outdoors and washing her hands with running cold water. This episode lasted 2-3 weeks and she did not have any more outbreaks of urticaria until March 2020, when she was prescribed amoxicillin-clavulanate again for 10 days due to cystitis. A week after completing the antibiotic treatment, she reported once more an outbreak of generalized urticaria in the corporal areas exposed while being outdoors (hands, face and neckline), also after washing her hands with cold water or even after sitting on cold stone benches, she had wheals on her buttocks. The ambient temperature was approximately 10°C typical in Galicia (northwest of Spain). Cutaneous lesions disappeared in about 30 minutes after warming her up. She felt that these episodes were more intense, (greater area and number of annoying, long lasting lesions). Outbreaks resolved after 2-3 weeks and she even was able to bath in sea water in summer of 2020, in Galicia's beach (Atlantic Ocean average temperature 15°C); and to eat an ice-cream and cold drinks without reaction, she had none outbreaks when doused with cold water. She is now asymptomatic.

Allergy study was performed with prick and intradermal reaction tests with Penicillin and Beta-lactam derivatives: BP-OL (Benzylpenicilil Octa L-lisine) and DM (Sodium Benzylpeniloate) from Diater Laboratories (Madrid, Spain), Penicillin G, Ampicillin, Amoxicillin, Amoxicillin-clavulanate, Cefuroxime and Ceftriaxone with negative results in immediate and late reading.

Skin prick tests with aeroallergens and staple foods in our area, latex, anisakis and panallergens as lipid transfer protein (LTP) and profillin (commercial extracts ALK-Abelló Laboratories) were performed with positive result for Dermatophagoides pteronyssinus and Lepidoglyphus destructor, without clinical repercussions.

Since ColdU was suspected, an ice cube test was performed with exposure for 5, 10, 15 and 30 minutes with negative results.

General blood analysis was performed: complete blood count, basic biochemistry, thyroid hormones, antithyroid antibodies, proteinogram, cryoglobulins and cold agglutinins, all within normal parameters. Total IgE 69 IU/ml, Dematophagoides pteronyssinus 5.21 KU/L, rDerp1 1.38 KU/L, rDerp2 1.68 KU/L, rDerp23 1.6 KU/L, Lepidoglyphus destructor 3.79 KU/L. sIgEs for Penicillin G, Penicillin V, Ampicillin, Amoxicillin and Clavulanic acid were negative.

Given the negative allergy study, an oral challenge test with Amoxicillin-clavulanic acid with pre and post ice cube test was scheduled. Cube test prior to the oral provocation test was negative. The oral tolerance test with Amoxicillin-clavulanate up to 1000 mg was carried out with correct tolerance. An ice cube test was performed 2 hours after finishing the last dose of Amoxicillin-clavulanate, being positive within 5 minutes exposure.

ColdU secondary to amoxicillin-clavulanic acid was confirmed. After the oral provocation test, the patient presented outbreaks of ColdU again for a week, which later resolved. The patient was scheduled for an oral challenge test with Cefuroxime with previous and post ice cube test with a negative result, confirming Cefuroxime tolerance without triggering cold urticaria.

Many attempts were made to complete amoxicillin oral challenge (without clavulanic acid) to reach a more precise diagnosis, but it was impossible because the patient rejected it, so the ban on amoxicillin and clavulanic acid (which is linked to amoxicillin) was maintained.

The pathogenesis of ColdU is not well defined, but the release of mast cell mediators seems to be an essential component. Histamine, prostaglandin D₂, platelet-activating factor, and tumor necrosis factor α have been found in the skin and serum of patients with ColdU [1,4]. ColdU can be divided into the typical symptoms that can be reproduced by cold stimulation, but also in atypical cold-

induced wheals or atypical response to cold stimulation [4]. Moreover, ColdU can be also classify in primary (idiopathic) and secondary form. Several causes of secondary ColdU have been described such infections, autoimmune or lymphoproliferative diseases, hymenoptera sting or certain drugs or foods [4,8]. Regarding to drugs, penicillin, combined oral contraceptives, angiotensin-converting enzyme inhibitors, anti-tetanus serum, griseofulvin [4] and alprazolam [9] had been described as potential causes or had clinical associations to ColdU. In addition, tattoo-induced ColdU has also been reported [10].

Symptoms of ColdU may vary from mild localized wheals to anaphylaxis. Due to the risk of anaphylaxis (21.49%) [2,3], an adrenaline auto-injector should be prescribed in some range of patients (with a cold provocation test of less than 3 minutes or with negative results [4]). In our patient, clinical presentations were exclusively cutaneous without systemic repercussions, symptoms were not only fleeting but also controlled just with antihistamines. Moreover, symptoms were only triggered when two factors coexisted: previous antibiotic treatment with amoxicillin/clavulanic-acid and cold exposure. This same pattern was described by Gandolfo-Cano et al [9] with alprazolam.

ColdU continues to be a pending topic for more research and studies, more case descriptions and case series are needed in order to better understand this clinical entity and its etiopathogenesis. We present this singular case, we have not found similar reports in the literature, of ColdU induced by Amoxicillin-clavulanic acid. It must be said that a more precise diagnosis could not be made with the oral challenge test with Amoxicillin (without clavulanic-acid) because the patient refused the test and due to the general shortage of standalone Amoxicillin (she consents to this publication).

Funding

The authors declare that no funding was received for the present study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

1. Wanderer AA. Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management. *J Allergy Clin Immunol* [Internet]. 1990 [cited 2022 Mar 21];85(6):965–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/2191995/>
2. Prosty C, Gabrielli S, Le M, Ensina LF, Zhang X, Netchiporouk E, et al. Prevalence, Management, and Anaphylaxis Risk of Cold Urticaria: A Systematic Review and Meta-Analysis. *J Allergy Clin Immunol Pract* [Internet]. 2022 Feb 1 [cited 2022 Mar 21];10(2):586-596.e4. Available from: <https://pubmed.ncbi.nlm.nih.gov/34673287/>
3. Deza G, Brasileiro A, Bertolín-Colilla M, Curto-Barredo L, Pujol RM, Giménez-Arnau AM. Acquired cold urticaria: Clinical features, particular phenotypes, and disease course in a tertiary care center cohort. *J Am Acad Dermatol* [Internet]. 2016 Nov 1 [cited 2022 Mar 21];75(5):918-924.e2. Available from: <https://pubmed.ncbi.nlm.nih.gov/27485164/>
4. Maltseva N, Borzova E, Fomina D, Bizjak M, Terhorst-Molawi D, Košnik M, et al. Cold urticaria - What we know and what we do not know. *Allergy* [Internet]. 2021 Apr 1 [cited 2022 Mar 21];76(4):1077–94. Available from: <https://pubmed.ncbi.nlm.nih.gov/33249577/>
5. Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CEH, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. *Allergy* [Internet]. 2016 Jun 1 [cited 2022 Mar 23];71(6):780–802. Available from: <https://pubmed.ncbi.nlm.nih.gov/26991006/>
6. Siebenhaar F, Weller K, Mlynek A, Magerl M, Altrichter S, Vieira Dos Santos R, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. *Clin Exp Dermatol* [Internet]. 2007 May [cited 2022 Mar 21];32(3):241–5. Available from: <https://pubmed.ncbi.nlm.nih.gov/17355280/>
7. Kulthanan K, Hunnangkul S, Tuchinda P, Chularojanamontri L, Weerasubpong P, Subchookul C, et al. Treatments of cold urticaria: A systematic review. *J Allergy Clin Immunol* [Internet]. 2019 Apr 1 [cited 2022 Mar 23];143(4):1311–31. Available from: <https://pubmed.ncbi.nlm.nih.gov/30776418/>

8. Kulthanan K, Tuchinda P, Chularojanamontri L, Maurer M. Food-dependent cold urticaria: A new variant of physical urticaria. *J allergy Clin Immunol Pract* [Internet]. 2018 Jul 1 [cited 2022 Mar 21];6(4):1400–2. Available from: <https://pubmed.ncbi.nlm.nih.gov/29698807/>
9. Gandolfo-Cano M, González-Mancebo E, González-de-Olano D, Meléndez- Baltanás A, Mohedano-Vicente E. Cold urticaria induced by alprazolam. *J Investig Allergol Clin Immunol* [Internet]. 2012 [cited 2022 Mar 23];22(3):222. Available from: <https://pubmed.ncbi.nlm.nih.gov/22697016/>
10. Raison-Peyron N, Litovsky J, Huet P, Dereure O. Cold contact urticaria triggered by a permanent tattoo. *J Cosmet Dermatol* [Internet]. 2021 Aug 1 [cited 2022 Mar 23];20(8):2463–5. Available from: <https://pubmed.ncbi.nlm.nih.gov/33251653/>

Accepted Article